Today, the FDA moved one step closer to approving the first OTC birth control pill in the US. Perrigo had applied for a switch from prescription-only to OTC status for its once-daily oral contraceptive named Opill. FDA could reach a final decision on t…
Hepatitis D is the most severe of all viral hepatitis infections, leading to quick onset of liver scarring and liver cancer. The pathogen that causes the disease, hepatitis D virus, is a virus like no other. What follows is an overview of its intricate…
Ads for gambling blanket the airwaves and social media sites. While the U.S. advertising blitz is in full swing, many nations in Europe are moving to place strict limits on promotions or abolish betting ads altogether.
This is the first of two stories describing recent progress in understanding the cause and potential treatment for osteoarthritis.
The Dobbs decision blocks non-pregnant female patients from receiving medications, like methotrexate, used to treat their autoimmune diseases. This could be just the beginning of government overreach for girls, women, and their families.
Until lecanemab and donanemab are granted regular FDA approval it’s very unlikely there will be a change in CMS’s current severely restrictive coverage policy. Once approved CMS will be inclined to relax coverage limits. This said, upon approval unfett…
Until lecanemab and donanemab are granted regular FDA approval it’s very unlikely there will be a change in CMS’s current severely restrictive coverage policy. Once approved CMS will be inclined to relax coverage limits. This said, upon approval unfett…
In a study published last month, Dutch researchers suggest that use of birth control pills near the time of conception may increase certain pregnancy risks. Specifically, use of oral contraceptives is associated with a modest increase in risk of preecl…
Gene therapies are still hampered by substantial delays between their date of approval and the time they launch. And it isn’t simply a matter of not having a payment or reimbursement system in place. Manufacturing and patient preparation delays figure …
The important takeaway is that these gene therapies can be cost-effective and don’t break the bank. Too often the discussion of a therapeutic’s price is fixated on eye-popping numbers and not value. It’s laudable that ICER has redirected us to the disc…
